Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages

  Cornel, Karlijn M C ^a   Kruitwagen, Roy F P M ^a   Delvoux, Bert ^a   Visconti, Laura ^a   Van De Vijver, Koen K ^a,c   Day, Joanna M ^b   Van Gorp, Toon ^a   Hermans, Rob J J ^a   Dunselman, Gerard A ^a   Romano, Andrea ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL 17BETA DEHYDROGENASE TYPE 1; ESTRADIOL 17BETA DEHYDROGENASE TYPE 12; ESTRADIOL 17BETA DEHYDROGENASE TYPE 5; ESTRADIOL 17BETA DEHYDROGENASE TYPE 7; ESTROGEN RECEPTOR ALPHA; ESTRONE; MESSENGER RNA; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 12; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 2; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 4; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 5; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 7; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 8; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ESTROGEN METABOLISM; EX VIVO STUDY; EXPLANT; FEMALE; GENE OVEREXPRESSION; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; ESTRADIOL DEHYDROGENASES; ESTROGEN RECEPTOR ALPHA; ESTRONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TISSUE CULTURE TECHNIQUES;

EID: 84859526377     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2994     Document Type: Article

References (40)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I 2005 Endometrial cancer. Lancet 366:491-505 (Pubitemid 41111699)
2. Gehrig PA, Bae-Jump VL 2010 Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116:187-194
3. Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, Guillemette C 2011 Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 96:E330-E339
4. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152-182 (Pubitemid 36515283)
5. Lonning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M 2011 Recent data on intratumor estrogens in breast cancer. Steroids 76:786-791
6. Berstein L, Zimarina T, Kovalevskij A, Maximov S, Volkov O, Thijssen JH 2005 CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. Neoplasma 52:115-118
7. Ito K, Utsunomiya H, Niikura H, Yaegashi N, Sasano H 2011 Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol Cell Endocrinol 340:161-167
8. Prehn C, Möller G, Adamski J 2009 Recent advances in 17β-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 114: 72-77
9. Moeller G, Adamski J 2009 Integrated view on 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 301:7-19
10. Moeller G, Adamski J 2006 Multifunctionality of human 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248:47-55
11. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A 2009 Increased production of 17β-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab 94:876-883
12. Boruban MC, Altundag K, Kilic GS, Blankstein J 2008 From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 17:133-138 (Pubitemid 351301624)
13. Smuc T, Rizner TL 2009 Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 301:74-82
14. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM 2010 Suppressed expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol 3:608-617
15. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM 2006 AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 248:126-135
16. Laplante Y, Rancourt C, Poirier D 2009 Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol Cell Endocrinol 301:146-153
17. Colette S, Lousse JC, Defrère S, Curaba M, Heilier JF, Van Langendonckt A, Mestdagt M, Foidart JM, Loumaye E, Donnez J 2009 Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod 24:2133-2141
18. Krasner C 2007 Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol 106:76-80 (Pubitemid 47362641)
19. Dassen H, Punyadeera C, Delvoux B, Schulkens I, Marchetti C, Kamps R, Klomp J, Dijks F, de Goeij A, D'Hooghe T, Kyama C, Ederveen A, Dunselman G, Groothuis P, Romano A 2010 Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signalling. Am J Pathol 177:2495-2508
20. Delvoux B, Husen B, Aldenhoff Y, Koole L, Dunselman G, Thole H, Groothuis P 2007 A sensitive HPLC method for the assessment of metabolic conversion of estrogens. J Steroid Biochem Mol Biol 104: 246-251 (Pubitemid 46891817)
21. Allred DC, Harvey JM, Berardo M, Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168 (Pubitemid 28144151)
22. Romano A, Adriaens M, Kuenen S, Delvoux B, Dunselman G, Evelo C, Groothuis P 2010 Identification of novel ER-α target genes in breast cancer cells: Gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17β-estradiol and tamoxifen. Mol Cell Endocrinol 314:90-100
23. Romano A, Delvoux B, Fischer DC, Groothuis P 2007 The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 38:331-350 (Pubitemid 46351613)
24. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A 2008 17β-Hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 122:1931-1940 (Pubitemid 351441181)
25. Burczynski ME, Harvey RG, Penning TM 1998 Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37:6781-6790 (Pubitemid 28228113)
26. Groothuis PG, Dassen HH, Romano A, Punyadeera C 2007 Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum Reprod Update 13:405-417 (Pubitemid 47062832)
27. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, Konishi I 2004 Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23:8603-8610 (Pubitemid 39576467)
28. Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C 2010 Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 95:2689-2698
29. Byrns MC, Duan L, Lee SH, Blair IA, Penning TM 2010 Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its overexpression in breast cancer. J Steroid Biochem Mol Biol 118:177-187
30. Fournier MA, Poirier D 2009 Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17β-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12). Mol Cell Endocrinol 301:142-145
31. Luu-The V, Tremblay P, Labrie F 2006 Characterization of type 12 17β-hydroxysteroid dehydrogenase, an isoform of type 3 17β- hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 20:437-443 (Pubitemid 43152516)
32. Jongen VH, Thijssen JH, Hollema H, Donker GH, Santema JG, Van der Zee AG, Heineman MJ 2005 Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer 15:529-536 (Pubitemid 40705552)
33. Utsunomiya H, Ito K, Suzuki T, Kitamura T, Kaneko C, Nakata T, Niikura H, Okamura K, Yaegashi N, Sasano H 2004 Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 10:5850-5856 (Pubitemid 39180965)
34. Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A 2008 The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 149:4035-4042
35. Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV 2005 Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26:171-202
36. Saloniemi T, Järvensivu P, Koskimies P, Jokela H, Lamminen T, Ghaem-Maghami S, Dina R, Damdimopoulou P, Mäkelä S, Perheentupa A, Kujari H, Brosens J, Poutanen M 2010 Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. Am J Pathol 176:1443-1451
37. Day JM, Tutill HJ, Purohit A, Reed MJ 2008 Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15:665-692
38. Poirier D 2010 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 20:1123-1145
39. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, Henn C, Hartmann RW, Frotscher M 2011 New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. J Med Chem 54:534-547
40. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H 2006 Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 248:109-113